Cardiac Myosin Inhibitors

Pushing Back Against HCM: The Role of Cardiac Myosin Inhibitors

Understanding Cardiac Myosin Inhibitors – A New Treatment Option for Hypertrophic Cardiomyopathy

Piedmont Heart Institute

New Frontiers in Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors

Emory Cardiology

Cardiac Myosin Inhibitors and HCM: Therapy of the (Near) Future

Cardiology University of Washington

Hypertrophic Cardiomyopathy: Myosin Inhibitors in Context | Rob Fraser, MD

Minneapolis Heart Institute Foundation

New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy

Aficamten: One More Cardiac Myosin Inhibitor for HOCM

Johnson Francis, MBBS, MD, DM

Aficamten: One More Cardiac Myosin Inhibitor for HOCM

Johnson Francis, MBBS, MD, DM

Cardiac Myosin Inhibition: Remodeling Clinical Workflows in oHCM and Beyond

PeerView Oncology

Aficamten: A New Cardiac Myosin Inhibitor for Hypertrophic Obstructive Cardiomyopathy

Johnson's Cardiology And Medicine

Aficamten: A New Cardiac Myosin Inhibitor for Hypertrophic Obstructive Cardiomyopathy

Johnson's Cardiology And Medicine

Choosing Therapy for Hypertrophic Obstructive Cardiomyopathy in the Era of Cardiac Myosin Inhibitors

The Texas Heart Institute

Bighearted Warriors Unite Special Edition Myosin Inhibitors

4hcm

Navigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients - HCMS Podcast Episode 12

2024 ACC/AHA/Multisociety Guidelines for Management of Hypertrophic Cardiomyopathy Released

Johnson Francis, MBBS, MD, DM

Aficamten for Obstructive Hypertrophic Cardiomyopathy | NEJM

New Drug Therapies in Hypertrophic Cardiomyopathy

2024 Guideline for the Management of Hypertrophic Cardiomyopathy

Targeted Medication for Hypertrophic Cardiomyopathy

Cleveland Clinic

CMUK Conference 2021 - Medication and Treatment - Dr Robert Cooper

Cardiomyopathy UK